ClinicalTrials.gg
RecruitingNCT05849285Updated Feb 27, 2026

Evaluation of the Transitional and Lifelong Care Program

An observational study in Cerebral Palsy, Spina Bifida and Developmental Disability, sponsored by Western University, Canada. Recruiting at 1 site in Canada. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Western University, Canada · Observational

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
410
Ages
21 Years and older
Sex
All
01

Study summary

The population cared for in the Transitional and Lifelong Care (TLC) clinic is youth and adults with childhood-onset disability, of which the large majority are adults with brain-based, neurodevelopmental conditions such as cerebral palsy, spina bifida and developmental disability. The TLC program was created to address the health inequities that have long existed for this population because of the gaps in care they experience once they transition from pediatric healthcare services to the adult healthcare sector. The TLC program offers coordinated and comprehensive management of co-occurring mental, social and physical health conditions for this group of adults with neurodiverse conditions. The proposed study will provide much needed evaluation of the TLC model as an intervention to provide transitional and lifelong care that reduces the barriers experienced because of the undefined clinic path - potentially more appropriately referred to as a "cliff" by a Freeman et al., (2015) - for these individuals. With appropriate evidence of effectiveness, scaling of the TLC program to other Ontario Health regions and more widely across Canada would improve access healthcare providers who are knowledgeable and competent in the management of physical and mental health conditions for adults with neurodiverse conditions as well as service integration and coordination between social and health sectors. The TLC clinic was co-designed with adults with neurodiverse conditions and health care providers in 2014 and represents a significant and sustainable change in the way healthcare has been delivered for this population in the Ontario Health West region over the last 7 years. More than 750 people have accessed coordinated and comprehensive care from Physiatrists, a Nurse Practitioner, Social Worker, Physiotherapist, Occupational Therapist, Speech Language Pathologist, Registered Dietitian and Rehabilitation Therapist in the TLC program since it began, documenting the effectiveness of this care has the power to re-shape care received for adults with neurodiverse conditions that onset in childhood in Canada.

02

Conditions studied

  • Cerebral Palsy
  • Spina Bifida
  • Developmental Disability
03

In context

Cerebral Palsy

1,936 studies on the registry are indexed under Cerebral Palsy; 458 are open to participants now.

This study's planned enrollment of 410 is above the median of 63 across 472 observational studies indexed under Cerebral Palsy.

Browse Cerebral Palsy studies →

Lead sponsor

Western University, Canada is the lead sponsor of 224 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Participants will be categorized into two cohorts: 1) patients of the TLC program, 2) controls . Participant dyads will be formed that include the adult patient (and a caregiver, spouse, or support person that may be involved in the patient's care. TLC dyads will be recruited from the existing client base of the program and control dyads will be recruited from the Kitchener/Waterloo/Cambridge area of Ontario (and the surrounding rural areas).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Each participant dyad will consist of one person, of either sex and gender, who is over the age of 21 years with a childhood-onset disability, and the primary caregiver (based on contact hours) or support person, of either sex and gender, involved in their care. In cases where the patient participant is independent with care, a spouse or family member may still participate in the caregiver portion of the study.

2. Patient participants will have continuously resided in Ontario during the years of 2015 to 2020 to facilitate full data retrieval from the administrative dataset.

3. Healthcare providers, of any discipline, who provide care to adults with childhood-onset conditions in the TLC program.

Exclusion criteria

Exclusion Criteria:

Patient participants will be ineligible if they are in a phase of deterioration associated with a progressive health condition identified either personally or by the caregiver participant.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
410 participants (estimated)
Patient registry
No

Groups and cohorts

  • TLC Patient

    Patients of the TLC program with CP/SB/DD

    Other: TLC Clinic

  • Control Patient

    Adults with CP/SB/DD that are not patients of the TLC Program

  • TLC Caregiver

    Caregiver of Patients of the TLC program with CP/SB/DD

    Other: TLC Clinic

  • Control Caregiver

    Caregiver of Adults with CP/SB/DD that are not patients of the TLC Program

  • Healthcare Providers

    Healthcare Providers who care for patients in the TLC clinic

    Other: TLC Clinic

Interventions

  • OtherTLC Clinic

    Patients of the TLC clinic - receive coordinated multidisciplinary and specialized care from a team

06

What researchers measure

Primary outcomes

  1. Patient Satisfaction

    MPOC-A (Measure of Processes of Care - Adults) Each domain score, ranging from 0.0 to 7.0, is computed by averaging the ratings for the items of that domain, higher scores represent better outcomes

    Time frame: Year 1

Secondary outcomes

  1. Health Related Quality of Life (General)

    EQ5D5L The five levels in each dimension are worded as (1) 'not /no problems', (2) 'slight problems', (3) 'moderate problems', (4) 'severe problems', and (5) 'unable to' (mobility, self-care, usual activities), 'extreme' (pain/depression), or 'extremely' (anxiety/depression). The descriptive system describes 3125 (=5⁵) potential health states.

    Time frame: Year 1

  2. Health Related Quality of Life (WHO)

    WHOQOL-BREF (World Health Organization Quality of Life - Brief) Lowest and highest possible scores to zero and 100, respectively. Higher scores represent better outcomes

    Time frame: Year 1

  3. Caregiver Burden

    BSFC (Burden Scale for Family Caregivers). Minimum score is 0, maximum score is 84, higher scores represent worse outcome (more burden).

    Time frame: Year 1

  4. Perceived Support of Healthcare Providers

    MPOC-SP (Measure of Processes of Care - Service Providers). Each domain score, ranging from 0.0 to 7.0, is computed by averaging the ratings for the items of that domain, higher scores represent better outcomes

    Time frame: Year 1

  5. Economic Analysis

    Unit Costs of healthcare used

    Time frame: Year 2

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — De-identified data will be available to share upon request made by other researchers once a plan of analysis has been proposed to the team

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05849285
Responsible party
Laura Brunton (Assistant Professor, Western University, Canada) — Principal investigator
First posted
May 8, 2023
Start date
Jan 3, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Feb 27, 2026

Study contacts

Laura K Brunton, PhD
Contact
lbrunto3@uwo.ca
15196612111 ext. 81501
Josh Wiener, MSc
Contact
jwiener2@uwo.ca
Laura K Brunton, PhD
principal investigator · Western University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion